The Capitalbio Co Ltd was set up on Sept 30, 2000 with a registered capital of 376.5 million yuan ($59.65 million). It aims at developing an integrated health care field including prediction, prophylaxis and personalized health care. It provides innovative products and services with the support of Tsinghua University and the Chinese Academy of Medical Science. It has developed more than ten independent intellectual property products including genes, proteins, cell chips and labonachip and relevant apparatus and instruments, reagents, supplies and software databases.

The company's several products have registered medical devices regulated by the China State Food and Drug Administration, passed the European CE authentication and achieved the US Food and Drug Administration's record of security customs clearance. Its products and services are exported to more than 20 countries and regions in North America, Europe, Asia and the Middle East. Its chip products are widely acclaimed by nearly one hundred hospitals in European countries including the UK, France, Germany, Italy, Spain, Denmark, Switzerland and Sweden.

The company's total assets had reached 587 million yuan by the end of 2007. The research and development (R&D), production and operation facilities cover a total area of 24,000 square meters. This includes the clinical diagnosis microarray chip, GMP auxiliary reagent manufacturing plant, silicone-based and plastics-based microfluidic chip micromachining clean shop and biochip manufacturing plants.

The company wholly owns two independent corporative business enterprises abroad: Capitalbio Hong Kong and CapitalBio International based in San Diego, California. It also has two holding companies home and abroad: the Aviva Biosciences Co and Shenzhen Chipscreen Biosciences Co Ltd, with more than 400 employees.

It was the only Asian company selected as the Global Most Promising Biotech Company in 2002 by the US Fortune magazine. The Fortune magazine published articles in 2004 that Capitalbio had become the first biotech enterprise in China that met international standards. It was also selected as one of the eight biotech enterprises in the Top 100 Asian Non-Listed Technology Enterprises by the US Red Herring magazine in 2005.

It won the first prize of Deloitte Technology Fast 50 China and was selected by the British Nature magazine as the recommended microarray products and services provider in 2006.